Piper Lists Eight Defensive Biotechs to Face Market Volatility
Legend Biotech (LEGN) Gets a Hold From William Blair
Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday
Genscript Bio (01548.HK): Legend Biotech's net loss for the first half of the year significantly narrowed, with R&D expenses reaching 0.214 billion US dollars.
Genscript Bio (01548.HK) announced that Legend Biotech Co., Ltd., a subsidiary listed on the market, had license revenue of 103.0 million US dollars for the six months ended June 30, 2024, compared with 15.1 million US dollars in the same period last year.
Genscript Bio (01548): Legend Biotech's total revenue in the first half of the year was USD 0.2805 billion, with a year-on-year increase of 155.8%.
Genscript Bio (01548) announced that its subsidiary, Legend Biotech Limited, is not a wholly-owned subsidiary of the company...
Legend biotech (LEGN.US) had a total revenue of 0.187 billion US dollars in Q2, a year-on-year growth of 155.01%.
Legend biotech (LEGN.US) announced its financial results for the second quarter and first half of 2024. The total revenue for the second quarter of 2024 was $0.187 billion, a year-on-year increase of 155.01% from $73.33 million in the same period last year. Among them, licensing revenue was $90.846 million, compared to $15.115 million in the same period last year, and collaborative revenue was $93.254 million, compared to $58.152 million in the same period last year. The net loss for the second quarter of 2024 was $18.196 million, compared to a net loss of $0.1991 billion in the same period last year. It belongs to the mother company ordinary.
